Clinical Trials
26
Active:14
Completed:5
Trial Phases
4 Phases
Phase 1:8
Phase 2:9
Phase 3:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Phase 2
9 (36.0%)Phase 1
8 (32.0%)Not Applicable
5 (20.0%)Phase 3
3 (12.0%)Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Not Applicable
Not yet recruiting
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 65
- Registration Number
- NCT07149363
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
Not Applicable
Not yet recruiting
- Conditions
- Advanced CancerMetastatic Cancer
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 1000
- Registration Number
- NCT06963723
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 178
- Registration Number
- NCT05798663
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Kaiser Permanente Oakland Medical Center, Oakland, California, United States
🇺🇸Kaiser Permanente Roseville Medical Center, Roseville, California, United States
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Phase 1
Withdrawn
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Registration Number
- NCT05408026
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Phase 1
Recruiting
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 148
- Registration Number
- NCT04486352
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Medstar Georgetown Cancer Institute, Washington D.C., District of Columbia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found